Panel Discussion on AHA Symposium: Clinical Rundown—3 Hot Topic Sessions on ASCVD Risk Reduction

Panel Discussion on AHA Symposium: Clinical Rundown—3 Hot Topic Sessions on ASCVD Risk Reduction

Panel Discussion on AHA Symposium: Clinical Rundown—3 Hot Topic Sessions on ASCVD Risk Reduction
RestartResume

Want tips for managing your patients with ASCVD? Tune in for highlights of late-breaking data that were presented at an AHA satellite symposium.

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    This CME Roundtable highlights key takeaways and late-breaking data shared at a symposium held at the AHA annual meeting. Hear updated management strategies, new data, and guidelines to help you manage patients with established ASCVD who are at an increased risk of myocardial infarction, stroke, and death.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Peter Libby, MD
    Mallinckrodt Professor of Medicine, Harvard Medical School
    Brigham and Women's Hospital, Division of Cardiovascular Medicine
    Boston, MA 

    Contracted Research: Novartis
    Consulting Fees: Amgen, Corvidia Therapeutics, CSL Behring, DalCor Pharmaceuticals, Kancera, Kowa Pharmaceuticals, MedImmune, Novartis, Olatec Therapeutics, PlaqueTec, XBiotech, Inc.
    Unpaid consultant to, or involved in clinical trials: Amgen, AstraZeneca, Baim Institute, Beren Therapeutics, Esperion Therapeutics, Genentech, Kancera, Kowa Pharmaceuticals, MedImmune, Merck, Norvo Nordisk, Novartis, Pfizer, Sanofi-Regeneron
    Ownership lnterest: XBiotech, Inc. 
    Received Funding Support: The National Heart, Lung, and Blood Institute, the American Heart Association, the RRM Charitable Fund, and the Simard Fund

    Faculty:
    Lawrence A. Leiter, MD

    Professor of Medicine and Nutritional Sciences
    University of Toronto,
    Toronto, Ontario, Canada 

    Consulting Fees: Amarin, AstraZeneca, Amgen, Esperion, HLS, Merck, Novartis, Pfizer, Sanofi
    Fees for Non-CME Services Received Directly from Commercial Interest: Amarin, AstraZeneca, Amgen, HLS, Merck, Novartis, Sanofi
    Contracted Research: Amgen, Kowa, Novartis, Sanofi, The Medicines Company 

    Prof. Kausik Ray
    Professor of Public Health, Imperial College London
    London, UK 

    Consulting Fees: Abbott, Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Esperion, Kowa, New Amsterdam, Novartis, Novo Nordisk, Pfizer, Resverlogix, Silence Therapeutics
    Commercial Interest Speakers Bureau: Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Lupin, Novartis, Novo Nordisk, Pfizer, Sanofi
    Contracted Research: Amgen, Daiichi Sankyo, Regeneron
    Ownership lnterest: Pemi31 Therapeutics 

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Ben Caref, PhD, has nothing to disclose.
    • Anna Trentini has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    1. Discuss recent omega-3 fatty acid outcomes trial results and their clinical implications in reducing ASCVD events
    2. Describe the clinical utility of statin-adjunct therapies for ASCVD event reduction
    3. Apply recent randomized clinical trial and evidence-based guidelines to reduce ASCVD risk
  • Target Audience

    This activity is designed to meet the educational needs of cardiologists, lipidologists, internists, diabetologists, and endocrinologists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this Panel Discussion activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 15 minutes of nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by independent educational grants from Amarin Pharma, Inc., and Esperion Therapeutics.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

Register

We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free